Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325650 · ClinicalTrials.gov registry record · Phase 3
Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,420
- Enrollment target
NCT00325650 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 2,420 participants.
The verdict
NCT00325650, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,420 participants
- Enrollment target
Study Summary
Primary objective: To evaluate the effect of long-term administration of Rimonabant on the time of progression to type 2 diabetes in patients with prediabetes (i.e. Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT) or both at baseline). Secondary objectives: * To assess the effect on weight loss and weight maintenance; sustained effect following a washout period, effect on other markers of glycemic control (fasting glucose, fasting-insulin and HbA1c), glucose tolerance and insulin responses during oral glucose tolerance tests (OGTTs), and on other risk factors (HDL-Cholesterol, TG), * To assess the effect on quality of life * To evaluate long term safety and tolerability.
Interventions
- DRUG Rimonabant
- DRUG Placebo (for Rimonabant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,420 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00325650
The ClinicalTrials.gov registry entry for NCT00325650 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rimonabant is the first listed.
NCT00325650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00325650 about?
NCT00325650 is a clinical study titled "Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes". Primary objective: To evaluate the effect of long-term administration of Rimonabant on the time of progression to type 2 diabetes in patients with prediabetes (i.e. Impaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT) or both at baseline). Secondary objectives: * To assess the effec...
What is the current status of trial NCT00325650?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,420 participants. The study started on 2006-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00325650?
The interventions under investigation include: Rimonabant (DRUG), Placebo (for Rimonabant) (DRUG).
Who is sponsoring clinical trial NCT00325650?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.